



# PHARMSOL NEWS

## REALIGNMENT IN DRUG SUBSTANCES INDUSTRY POST COVID 19

APRIL 2020 EDITION

PSNL/0007/04/2020



*"The nature as they say has its own checks & balances and it regulates itself"*

PharmSol and its expert teams analyzed the Pre-COVID / Post COVID pandemic w.r.t API / Drug substances industries. We are delighted to bring up this evaluation and how the world shall transpire, its re-emergence in particular to API industries.

In 1950s to 70s and in the Post World War II situation, there was an emergence of new world order where food scarcity, contaminated water bodies lead to discoveries in antibacterial for treatment of Cholerae, Vaccines for Viral infections like Small Pox, Chicken pox, Antimalarials, drug substances for Topical diseases



Late 70s, saw the World becoming more focused in to electronics and advanced research into allied & applied industries which lead to increment in life style disease like Diabetics, Hypertension, Cardio vascular ailments. This had a shift in inventions & drug discoveries in to Drug substances for its cure. While this segment was getting attention, due to more serene life, de-nucleated families it took serious effect on mental health where many Psychotropic drug substances had also given a thrust area and many drug discoveries surged in

In the 90s, human immunodeficiency virus made a havoc and researchers focused on Antiretroviral & HIV medicines. It also saw oncology as an area for drug discoveries leading to many new Anticancer drug substances and with many of them still under patent.

Off late there has been major spurt of Finished dosage forms manufacturers across the globe and API production has been sized too few of specific geographies. Only handful of those finished dosage form manufacturing companies

have their in-house API manufacturing for captive consumption

COVID 19 Pandemic which no one anticipated to have such to huge toll on the global population besides having its lasting impact on the economy. Irrespective the optimism, it shall take couple of years to get back on track to come out of recession.

With every corner of the globe reporting COVID, this is leading to a new emergence of a situation wherein Drug substances manufacture & indigeneity will be needed to avoid imbalances in drug shortage.

The number of API companies across the globe were either reduced & concentrated into few pockets since late 90s. While new research will definitely be ongoing in to new moieties, our experts opine that this will have a shift for good in the existing drug substances which shall forge into

- ◇ Establishing new API factories in various quartets
- ◇ Self-sufficiency, export of APIs
- ◇ Relooking in to new advanced intermediates manufacturing with Green Chemistry
- ◇ Enhancing the API manufacturing abilities
- ◇ Enhancing Process economies to have cost effective
- ◇ Old APIs with new economical process
- ◇ Revisiting drug resistance with prodrugs



**PharmSol with its look ahead strategy Post Covid 19, is offering guidance and its expertise on the Process know-how for many APIs, Process optimizations & innovative models to stay thru put in APIs.**

**You may contact us [info@pharm-sol.com](mailto:info@pharm-sol.com)**

